Last month, the Italian government asked the World Health Assembly to adopt a resolution to require drug makers to disclose their R&D and production costs, as well as prices charged for medicines and vaccines. Italian health minister Giulia Grillo wrote to the World Health Organization that “international action is required to improve transparency” in order to widen access to pharmaceuticals. If the resolution is enacted, the WHO would have a mandate to collect and analyze data on clinical trial outcomes, assess patents, and provide a forum for countries to share information on prices, R&D and marketing costs, R&D subsidies, and public sector investments. In effect, the proposal would set an international standard, but is likely to get pushback from the pharmaceutical industry. We spoke with Grillo, who publicly announced the move on Tuesday, about the effort. Her comments are from both an email exchange and a phone conversation. This interview has been lightly edited.

Pharmalot: Why did you propose this resolution?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy